Core Viewpoint - Qiming Medical-B (02500) has seen a stock increase of over 4%, currently trading at 2.48 HKD, with a transaction volume of 1.1562 million HKD, following the announcement of its CE MDR certification application for the Cardiovalve transcatheter tricuspid valve replacement system [1] Group 1 - The company has officially submitted all application materials for CE MDR certification of the Cardiovalve system to the European notification body, marking a significant step in the product's market entry process in Europe [1] - The Cardiovalve system is designed to treat both mitral and tricuspid regurgitation through a transcatheter intervention, enhancing treatment safety compared to similar products [1] - The product features a maximum 55mm valve ring design suitable for approximately 95% of patients, and its unique short valve frame design effectively reduces the risk of left ventricular outflow tract obstruction [1] Group 2 - The Cardiovalve system is characterized by its simple, safe, and reproducible operation, requiring only three steps: positioning, anchoring, and releasing [1]
港股异动 | 启明医疗-B(02500)涨超4% 三尖瓣置换产品Cardiovalve正式递交欧盟CE认证申请